Click on image to view larger version.

Figure 3 Reduction in the size of platelet thrombi exposed to blood containing different antagonists of platelet function. These experiments were performed as described in the caption of Figure 2, with the difference that the surface was exposed to two subsequent aliquots of blood each perfused for 6 min. (A) Representative images (0-degree and 90° projections) of platelet thrombi after perfusion of the first (before) or second (after) control blood aliquot (please see the online version of this article for supplemental videos). (B) Representative images of platelet thrombi after perfusion of the first control blood aliquot (before) or a second blood aliquot containing the P2Y₁₂ inhibitor AR-C69931MX (100 nmol/l) (please see the online version of this article for supplemental videos). (C) Cross-sectional area occupied by fluorescent platelets in horizontal planes passing through the thrombi at the indicated distance from the collagen surface, calculated as percentage of the area in the plane closest to collagen surface. The bars labeled "Before" show the area of thrombi formed after perfusion of untreated blood for 6 min. The bars labeled "No Addition," AR-C, MRS, and LAN show the area of thrombi remaining on the surface after an additional 6 min perfusion of untreated blood, or blood treated with the P2Y₁₂ inhibitor AR-C69931MX (100 nmol/l), or the P2Y₁ inhibitor MRS2179 (100 µmol/l), or the putative Ca²⁺ channel inhibitor lanthanum chloride (LAN) (1 mmol/l), respectively. Mean and SEM of eight experiments are shown.